Answers are grounded in this paper and cite their sources.
Purpose: Transcriptomic immune signatures are widely proposed as predictors of response to immune checkpoint inhibitors in metastatic urothelial carcinoma, but are almost always evaluated against chance rather than against the markers a clinician already has. We asked what such a signature adds to information that is already measured. Methods: We analyzed IMvigor210 ( n = 348 with pre-treatment tumor RNA sequencing; 298 evaluable for response). Six published immune signatures and two pre-specified control signatures were compared with two baselines: routine clinical variables (metastatic pattern, ECOG performance status, prior platinum), and those plus PD-L1 immunohistochemistry and tumor mutational burden. Discrimination was estimated as out-of-fold area under the curve over 50 repeats of stratified five-fold cross-validation; incremental value was tested by likelihood-ratio test. Overall survival was analyzed by Cox regression with Harrell’s C-index. Results: The clinical baseline reached an AUC of 0.697 (95% CI 0.619–0.767) and the extended baseline 0.778 (0.708–0.844). Tumor mutational burden alone reached 0.720 (0.639–0.796) and exceeded every immune signature in a paired comparison (ΔAUC −0.122 to −0.189). No immune signature added measurable information to either baseline (ΔAUC ≤ +0.003; likelihood-ratio p = 0.06–0.99), whereas a proliferation control did. Metastatic pattern explained 6.8–11.0% of signature variance and accounted for nearly all of the attenuation seen on adjustment. Conclusion: Established immune signatures carried no detectable incremental value over markers already measured in this cohort.
No takes yet. Share an insight, caveat, or question.
Karen Baghdasaryan (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: